At Worldwide, we address screen failure at its source. Before a study reaches site activation, our scientific and medical leaders pressure-test eligibility criteria, biomarker requirements, and endpoint definitions against the realities of digestive disease care across IBD, Crohn’s disease, ulcerative colitis, and celiac disease.
We’ll connect you with the right Digestive Diseases clinical development team
Why Digestive Disease Programs Demand Specialized Support
We combine biomarker-driven eligibility strategies grounded in real-world GI patient populations, protocol designs that accommodate fluctuations in disease activity, and dedicated teams that provide continuity throughout long study lifecycles. The result is lower enrollment risk, stronger endpoint integrity, and greater confidence in study outcomes.
Biomarker eligibility criteria can erode the available IBD patient pool long before the first patient is screened, yet the impact often remains hidden until recruitment falls behind plan.
Flares, changing disease activity and concomitant medications complicate eligibility throughout a GI autoimmune program.
Long-term endpoint acquisition in chronic GI disease depends on consistent site engagement, sympathetic assessment schedules and strong patient follow-through. Establishing these early avoids missed assessments, incomplete datasets, and risk to endpoint integrity.

Partnership & Approach
You will work with the same scientific, medical, and operational leads from the first scientific conversation through database lock. CRA turnover across our immunology and inflammation programs runs at 9.5% against an industry average closer to 25%, and CTM turnover at 2.45%, which keeps site relationships intact across a long GI program.
Digestive disease programs are anchored in the same eligibility design work that delivered three consecutive Phase II immunology and inflammation programs ahead of schedule.
Worldwide reduced the global screen failure rate by 7 percentage points on a Phase II autoimmune study by building a pre-screening registry of trial-ready eligible patients.
More than 50% faster than industry average, on a global Phase II Crohn’s disease program.
Three consecutive global Phase II autoimmune programs delivered Last Patient In ahead of schedule with site identification and enrollment running concurrently.
Why Worldwide for Digestive Diseases Trials
Attila Timar-Peregrin, MD, PhD, Therapeutic Area Lead for Digestive Diseases, brings more than 20 years as a principal investigator and subject matter expert across IBD, Crohn’s disease, ulcerative colitis, celiac disease, and GI motility disorders.
Fecal calprotectin and CRP thresholds are integrated into eligibility design at the protocol stage, with alignment between central and local endoscopy assessments validated before screening begins.
Experienced in agile solutions and adaptive protocols for programs where disease activity, flare timing, and concomitant medications shift eligibility throughout the study.
Frequently Asked Questions
We have answered the questions sponsors ask most often about digestive disease programs. If yours isn’t here, our autoimmune team is happy to help.
Yes. Worldwide has delivered digestive disease clinical trials across IBD, Crohn’s disease, ulcerative colitis and celiac disease, including biologic and biosimilar programs and adaptive designs built for GI autoimmune variability. Our leadership brings more than two decades of expertise across GI, autoimmune, and inflammatory conditions.
We address screen failure in protocol design. Before the first site is activated, senior scientific and medical reviewers pressure-test eligibility criteria, biomarker cutoffs, and endpoint definitions against real-world clinical practice. For IBD studies, that means optimizing fecal calprotectin and CRP thresholds and establishing concordance between central and local endoscopy reads before screening opens.
We build GI autoimmune variability into protocol design from the outset, anticipating the effects of flare timing, changing disease activity, and concomitant therapies before recruitment begins. When unforeseen challenges emerge, operational and scientific leaders work together in real time to resolve them, allowing studies to adapt quickly and maintain enrollment momentum without lengthy escalation processes.
The team you meet at bid defense is the team that stays with your study through database lock. By avoiding post-award handoffs and maintaining exceptionally low CRA (9.5%) and CTM (2.45%) turnover, we protect the site relationships, operational consistency, and study knowledge that are essential for retaining patients, capturing endpoints, and delivering long-duration GI trials on plan.
Chronic GI studies succeed or fail on patient retention. Yet protocols often require frequent site visits, invasive assessments, and lengthy maintenance periods when patients are feeling well and motivation can wane. We address this from the outset and work with our sponsors to build in flexibility into ePRO collection, enabling home health support for off-site lab assessments, and designing visit schedules around real-world employment, travel, and caregiving demands.